Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains

EU orphan designation number: EU/3/13/1179   
Active ingredient: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains
Indication: Treatment of growth hormone deficiency
Sponsor: Larode Ltd
Bridge House, High Street, Horam, Heathfield TN21 0EY, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
08/08/2013 Centralised Orphan - Designation EMA/OD/074/13 (2013)5278 of 05/08/2013